Pharmacokinetic Study on Ozagrel in Twelve Healthy Volunteers
JIN Rui1， SUN Kao-xiang2， WANG Zhen1，HAN Yu-bo1
Author information+
1.Institute of Clinical Pharmacy and Drug，Second Hospital Affiliated to Harbin Medical University，Harbin 150086，China；2. Yantai University of Pharmacology， Yantai 264005，China
{{custom_zuoZheDiZhi}}
{{custom_authorNodes}}
{{custom_bio.content}}
{{custom_bio.content}}
{{custom_authorNodes}}
Collapse
History+
Received
Published
2005-03-03
2006-02-10
Issue Date
2006-02-10
Abstract
OBJECTIVE To study the pharmacokinetic profiles of ozagrel in healthy Chinese volunteers.METHODS In a two period study,12 healthy male volunteers received a single dose and multiple-dose regimen of 200 mg ozagrel.The plasma concentrations of ozagrel were determined by HPLC.The pharmacokinetic parameters of ozagrel were calculated and analyzed with statistical method.RESULTS The concentration-time curves of a single dose and multiple-dose regimen were fit to a two-compartment open model with first-order absorption.The main pharmacokinetic parameters of a single-dose and multiple-dose regimen were as follows:AUC0-t(3.50±0.90)and(5.87±1.18)mg·h·L-1,AUC0-∞(3.73±0.91) and(6.32±1.29) mg·h·L-1,ρmax(3.10±1.06)and(5.12±1.37)mg·L-1,tmax(0.42±0.12)and((0.50±0.26)h),t1/2β(0.72±0.26) and(0.75±0.99)h,respectively.CONCLUSION The statistical analysis shows that there are significant difference after the treatment of a single dose and multiple-dose regimen.
JIN Rui;SUN Ko-xing;WNG Zhen;HN Yu-o.
Pharmacokinetic Study on Ozagrel in Twelve Healthy Volunteers [J]. Chinese Pharmaceutical Journal, 2006, 41(04): 296-298
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] SEKI H， KUROMAKI K， TAKEDA S，et al. Trial of prophylactic administration of TXA2 synthetase inhibitor， ozagrel hydrochloride，for preeclampsia[J] .Hypertens Pregnancy，1999，18(2)：157-164.
[2] OGISO T， IWAKI M， HARA Y，et al. Pharmacokinetics of ozagrel and its metabolites after intravenous and oral administrations[J] .Pharm Sci，1997，86(10)：1111-1114.
[3] ZHENG N X， SATO H， KOBAYSHI F，et al. Rectal absorption of ozagrel from a suppository containing its commercial tablet in healthy human subjects[J] .Biol Pharm Bull，1997，20(3)：282-284.
